0.787
전일 마감가:
$0.8149
열려 있는:
$0.8
하루 거래량:
1.98M
Relative Volume:
0.31
시가총액:
$165.39M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-1.0493
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
+11.54%
1개월 성능:
-6.22%
6개월 성능:
-47.53%
1년 성능:
+56.46%
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
명칭
Sangamo Therapeutics Inc
전화
(510) 970-6000
주소
501 CANAL BLVD., RICHMOND, CA
SGMO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SGMO
Sangamo Therapeutics Inc
|
0.787 | 165.39M | 52.29M | -134.84M | -117.11M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-13 | 업그레이드 | Truist | Hold → Buy |
2024-12-10 | 재확인 | H.C. Wainwright | Buy |
2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
2022-06-13 | 재개 | Wedbush | Neutral |
2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
2021-01-07 | 재개 | Guggenheim | Neutral |
2021-01-06 | 개시 | Stifel | Hold |
2020-12-16 | 재개 | H.C. Wainwright | Buy |
2020-09-08 | 개시 | BofA Securities | Buy |
2020-07-07 | 개시 | SunTrust | Buy |
2019-08-26 | 개시 | H.C. Wainwright | Buy |
2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
2018-10-10 | 개시 | Guggenheim | Buy |
2018-06-20 | 개시 | BofA/Merrill | Buy |
2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2017-06-22 | 재개 | Jefferies | Buy |
2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2015-12-04 | 개시 | Wells Fargo | Outperform |
2015-10-23 | 재개 | Jefferies | Buy |
2013-05-03 | 개시 | BioLogic Equity Research | Sell |
2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
2010-07-29 | 재확인 | Wedbush | Outperform |
2009-10-19 | 개시 | Brean Murray | Sell |
2009-10-07 | 재확인 | Leerink Swann | Outperform |
2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Zenopa
Sangamo announces capsid license agreement with Eli Lilly - MSN
Lilly, Sangamo Enter Capsid License Agreement - Contract Pharma
Another rebound as Sangamo inks $1.4B capsid deal with Lilly - BioWorld MedTech
Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha
Sangamo Thera enters critical deal with Lilly - The Pharma Letter
Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace
Lilly throws lifeline to Sangamo with $1.4bn licensing deal - pharmaphorum
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga
Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus
Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus
Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa
Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada
Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals
Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener
Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga
Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours - MarketScreener
Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com South Africa
Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com
Sangamo Therapeutics, Inc. (SGMO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
5 Best Stem Cell Companies to Invest In (April 2025) - Securities.io
Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com
Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart
Fabry Disease Market Growth Projections 2023-2032: - openPR
Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa
Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India
Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa
8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga
IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus.com
Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss By Investing.com - Investing.com South Africa
Sangamo: Q4 Earnings Snapshot - mySA
Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss - Investing.com
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Sangamo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sangamo Therapeutics Q4 2024 Earnings: EPS of -$0.11 Misses Esti - GuruFocus.com
Sangamo: Q4 Earnings Snapshot -March 17, 2025 at 04:36 pm EDT - Marketscreener.com
Sangamo Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada
Sangamo Therapeutics shares fall as Q4 results miss estimates By Investing.com - Investing.com Australia
Sangamo Therapeutics shares fall as Q4 results miss estimates - Investing.com India
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):